BMS, H3 Biomedicine evaluate RNA splicing technology

Bristol-Myers Squibb Co. (NYSE:BMY) and Eisai Co. Ltd. (Tokyo:4523), along with its subsidiary H3 Biomedicine, Inc. (Cambridge, Mass.), partnered to use H3’s RNA splicing platform to develop immunotherapies.

H3 and BMS will jointly conduct the research and the pharma will be responsible for development and commercialization of selected compounds. Eisai has an option to co-develop and co-commercialize selected compounds that emerge from the research. ...